22 COVID-19 vaccines enter clinical trials in China: health official
Share - WeChat

BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Delivering social benefits
- Shenzhou XIX crew returns safely to 'beautiful, blue' Earth
- Ordinary work, extraordinary workers
- AI agent to improve international law services in Shanghai
- Intl Services Shanghai expands reach with launch of Italian-language website, multimedia platforms
- China opened more than 900 national wetland parks in over two decades